Compounded GLP-1 access is changing. Here are your legal options.
The FDA shortages have resolved and large-scale compounding is being restricted. If your compounded GLP-1 is ending, here is what is happening and the legal paths forward.
The FDA declared the semaglutide and tirzepatide shortages resolved (tirzepatide December 2024, semaglutide February 2025), which narrowed the legal basis for large-scale compounding, and in April 2026 it proposed to permanently exclude these drugs from the bulk-compounding list. Large-scale (503B) compounding is being wound down, while patient-specific (503A) compounding continues in narrow cases. If your compounded GLP-1 is ending, your main legal paths are brand-name via insurance, a brand cash-pay program, or a local clinic. Talk to your prescriber before you run out.
What changed, and what did not
The short version: large-scale compounding is being restricted, but compounding is not categorically banned.
The FDA removed tirzepatide (December 2024) and semaglutide (February 2025) from its drug-shortage list. Much of the large-scale compounding that grew during the shortage relied on that shortage status, so the legal basis for it narrowed once the shortages ended.
In April 2026 the FDA proposed to permanently exclude semaglutide, tirzepatide, and liraglutide from the 503B outsourcing-facility bulks list. It is a proposal open for public comment through June 29, 2026, not a finalized rule. Outcomes may change.
Patient-specific (503A) compounding remains allowed in narrow situations, for example a documented allergy to an ingredient in the approved product, or a strength that is not commercially available. The change targets large-scale (503B) bulk compounding, not every compounded prescription. Whether you still qualify is a clinical decision for your prescriber.
What it costs to switch
Typical monthly cost for each legal path, compared with compounded pricing. Rates are anchors, not quotes; confirm current pricing with the program.
| Path | Typical monthly cost |
|---|---|
| Compounded GLP-1 (access ending)Large-scale access is narrowing in 2026 as the legal basis changes. | $150 to $300 |
| Brand-name via insurance + savings cardIf your plan covers a GLP-1, the manufacturer savings card applies on top. | $0 to $25 |
| Oral Wegovy (semaglutide pill), cashNovoCare cash-pay, priced by dose. No needles. | $149 to $299/mo |
| Zepbound (LillyDirect), cashSelf-pay vials or the Multi-Dose KwikPen, shipped. | from $299/mo |
| Foundayo (orforglipron), cashSelf-pay (priced by dose), or as low as $25/mo with commercial savings. | from $149/mo |
| Medicare GLP-1 BridgeEligible Part D members, prior authorization required, from July 1, 2026. | $50/mo |
Pricing verified June 18, 2026. The Medicare GLP-1 Bridge $50/mo rate and July 1, 2026 start apply to the Bridge program for eligible Part D members with prior authorization, not to Part D coverage generally.
Your three legal options
Most people land on one of these three. Which fits depends on your coverage, budget, and whether you want in-person care.
Online providers can prescribe legal GLP-1 options and ship to your door, often the fastest route if you already have a diagnosis on file.
Disclosure: some telehealth partners pay GLP1 Clinics a referral fee. It does not change your price.
Compare telehealth providersManufacturer programs sell brand-name GLP-1s directly, no insurance required. These are informational links; we earn nothing from them.
An obesity-medicine or GLP-1 clinic near you can manage the switch in person, coordinate insurance, and follow you over time. Browse our directory of GLP-1 clinics by state.
Find a clinicNot sure which path is right for you?
Take our 90-second quiz and we'll point you toward the legal option that fits your coverage, budget, and whether you want in-person care.
How to switch safely
Switching products is a clinical decision. Use these steps to prepare for the conversation with your prescriber.
- 1Do not stop abruptly
If your compounded supply is ending, talk to a prescriber before you run out. Stopping suddenly can bring appetite back and may affect the progress you have made.
- 2Confirm your current dose
Know exactly what you have been taking, the drug and the dose. Brand-name products come in set dose steps, so a prescriber can map you to the closest approved dose and titration plan.
- 3Ask about timing and overlap
Ask how to time the switch so you do not have a gap, and whether you need to step the dose up or down as you change products.
- 4Choose a legal path
Decide between insurance-covered brand, a cash-pay program, or a local clinic, based on your cost and your medical history. Your prescriber can help you weigh them.
The most important step is the first one: talk to your prescriber before your current supply runs out. They can map your dose, time the change, and pick a path that fits your medical history.
Frequently asked questions
Sources
- FDA, FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. Covers the resolution of the tirzepatide (December 2024) and semaglutide (February 2025) shortages and the compounding enforcement timelines. fda.gov
- FDA proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list, announced April 30, 2026. Public comment period through June 29, 2026 (Federal Register document 2026-08552, published May 1, 2026). federalregister.gov
- FDA, Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. Covers adverse-event reports and dosing-error risk. fda.gov
Regulatory statements are drawn from FDA drug-shortage records and the FDA proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list (comment period through June 29, 2026). Pricing reflects published manufacturer and program rates at the date above and should be re-verified before relying on it. This page is educational and not medical advice.